Proposed deal with Europe sparks debate in Canadian drug industry

There is a heated debate over Canada's intellectual property (IP) regime, and Canada stands to pay $2.8 billion more every year in drug costs while it undermines its generic-drug manufacturing sector, according to Edmonton Journal, Canadian daily newspaper.

The paper said that what's at stake is the viability of Canada's pharmaceutical research sector and a trade deal that could raise Canada...